Pfizer Inc. $PFE Shares Sold by Farmers Trust Co.

Key Points

• Farmers Trust Co. significantly reduced its holdings in Pfizer Inc. by 65.5% during the second quarter, leaving them with 77,818 shares valued at approximately $1.886 million.
• Pfizer reported a notable 10.3% increase in revenue year-over-year, achieving $14.65 billion for the quarter, exceeding analysts' expectations.
• The company declared a quarterly dividend of $0.43 per share, resulting in a 7.2% annual dividend yield with a payout ratio of 91.49%.

Farmers Trust Co. reduced its holdings in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 65.5% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 77,818 shares of the biopharmaceutical company's stock after selling 147,575 shares during the period. Farmers Trust Co.'s holdings in Pfizer were worth $1,886,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently added to or reduced their stakes in the business. Capital Advisory Group Advisory Services LLC grew its stake in Pfizer by 2.9% during the 2nd quarter. Capital Advisory Group Advisory Services LLC now owns 13,542 shares of the biopharmaceutical company's stock valued at $328,000 after purchasing an additional 388 shares during the last quarter. Trust Co of the South grew its stake in Pfizer by 1.5% during the 2nd quarter. Trust Co of the South now owns 29,386 shares of the biopharmaceutical company's stock valued at $712,000 after purchasing an additional 441 shares during the last quarter. Charter Oak Capital Management LLC grew its stake in Pfizer by 4.3% during the 2nd quarter. Charter Oak Capital Management LLC now owns 10,663 shares of the biopharmaceutical company's stock valued at $258,000 after purchasing an additional 444 shares during the last quarter. Members Trust Co grew its stake in Pfizer by 2.1% during the 1st quarter. Members Trust Co now owns 23,175 shares of the biopharmaceutical company's stock valued at $587,000 after purchasing an additional 467 shares during the last quarter. Finally, Sutton Place Investors LLC grew its stake in Pfizer by 5.6% during the 1st quarter. Sutton Place Investors LLC now owns 8,833 shares of the biopharmaceutical company's stock valued at $224,000 after purchasing an additional 472 shares during the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer Price Performance

Shares of Pfizer stock opened at $24.05 on Tuesday. The business has a 50 day simple moving average of $24.61 and a two-hundred day simple moving average of $24.18. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $30.43. The stock has a market capitalization of $136.74 billion, a P/E ratio of 12.79, a PEG ratio of 0.78 and a beta of 0.55. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85.

Pfizer (NYSE:PFE - Get Free Report) last announced its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, beating analysts' consensus estimates of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The business had revenue of $14.65 billion during the quarter, compared to analysts' expectations of $13.43 billion. During the same quarter in the prior year, the firm earned $0.60 earnings per share. The business's revenue was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, analysts predict that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Tuesday, September 2nd. Investors of record on Friday, July 25th were issued a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 7.2%. The ex-dividend date of this dividend was Friday, July 25th. Pfizer's dividend payout ratio (DPR) is currently 91.49%.

Analyst Upgrades and Downgrades

Several analysts have weighed in on the company. Citigroup boosted their price target on Pfizer from $25.00 to $26.00 and gave the company a "neutral" rating in a research note on Wednesday, August 6th. Bank of America upped their target price on Pfizer from $27.00 to $28.00 and gave the stock a "neutral" rating in a research note on Wednesday, August 6th. Morgan Stanley upped their target price on Pfizer from $32.00 to $33.00 and gave the stock an "equal weight" rating in a research note on Wednesday, August 6th. Berenberg Bank lowered their target price on Pfizer from $28.00 to $25.00 and set a "hold" rating on the stock in a research note on Thursday, May 29th. Finally, Wall Street Zen upgraded Pfizer from a "hold" rating to a "buy" rating in a research note on Saturday. Two analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, eleven have assigned a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Hold" and an average target price of $28.12.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.